

**DESCRIPTION**

**Source** Mouse myeloma cell line, NS0-derived mouse PDGF R alpha protein  
Leu25-Glu524, with a C-terminal 6-His tag  
Accession # P26618.3

**N-terminal Sequence Analysis** Leu25

**Predicted Molecular Mass** 57 kDa

**SPECIFICATIONS**

**SDS-PAGE** 86-97 kDa, reducing conditions

**Activity** Measured by its binding ability in a functional ELISA.  
When Recombinant Mouse PDGF R $\alpha$  is immobilized at 1  $\mu$ g/mL (100  $\mu$ L/well), the concentration of Recombinant Rat PDGF-AA (Catalog # 1055-AA) that produces 50% of the optimal binding response is 0.75-7.5 ng/mL.

**Endotoxin Level** <0.10 EU per 1  $\mu$ g of the protein by the LAL method.

**Purity** >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

**Formulation** Lyophilized from a 0.2  $\mu$ m filtered solution in PBS. See Certificate of Analysis for details.

**PREPARATION AND STORAGE**

**Reconstitution** Reconstitute at 500  $\mu$ g/mL in PBS.


**Shipping** The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

**Stability & Storage** Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months,  $\leq$  -20 °C under sterile conditions after reconstitution.


**DATA**

**Binding Activity**



When Recombinant Mouse PDGF R $\alpha$  (Catalog # 10065-PR) is coated at 1  $\mu$ g/mL, 100  $\mu$ L/well, Recombinant Rat PDGF-AA (Catalog # 1055-AA) binds with an ED<sub>50</sub> of 0.75-7.5 ng/mL.

**SDS-PAGE**



2  $\mu$ g/lane of Recombinant Mouse PDGF R $\alpha$  was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 86-97 kDa.

**BACKGROUND**

PDGF R $\alpha$  (platelet-derived growth factor receptor alpha) is a type I transmembrane glycoprotein in the class III subfamily of receptor tyrosine kinases (RTK) (1-3). PDGF R $\alpha$  and PDGF R $\beta$  can form homo- or hetero-dimeric receptors when engaged by dimers of the PDGF family of growth factors, which include disulfide-linked homodimers of PDGF-A, B, C or D, or the heterodimer PDGF-AB that is mainly found in human platelets. While multiple *in vitro* ligand-receptor combinations have been identified, *in vivo* evidence indicates that PDGF R $\alpha$  primarily binds PDGF-AA and PDGF-CC, while PDGF R $\beta$  primarily binds PDGF-BB and probably PDGF-DD. Like all class III RTKs, the extracellular domain (ECD) of mouse PDGF R $\alpha$  (amino acids 25-525) contains five immunoglobulin-like domains, while the intracellular region contains a split tyrosine kinase domain (aa 593-954). Within the ECD, mouse PDGF R $\alpha$  shares 85%, 93%, 84%, 84%, and 81% amino acid sequence identity with human, rat, equine, canine and bovine PDGF R $\alpha$  respectively. PDGF R $\alpha$  autophosphorylates upon dimerization, activating signaling cascades in PI 3-kinase Ras-MAP kinase, and PLC- $\gamma$  pathways (1, 2). Signaling is down-regulated by SHP-2 phosphatase activity and by receptor endocytosis and lysosomal degradation. PDGF R $\alpha$  is expressed at low levels in most mesenchymal cells, but is strongly expressed in oligodendrocyte, lung, skin and intestinal progenitor cells and induced by inflammation or growth in culture (1-3). During development, mesenchymal cells expressing PDGF R $\alpha$  respond to local gradients of epithelially produced PDGF-AA or PDGF-CC during formation of the cranial and cardiac neural crest, retina, gonads, lung alveoli, intestinal villi, skin, hair follicles, skeleton, teeth, palate, and interstitial kidney mesenchyme (1, 4). Deletion of PDGF R $\alpha$  in mice severely impairs mesenchymal derivatives in both embryo and extraembryonic tissues, and high or low PDGF R $\alpha$  signaling in humans may result in spina bifida or cleft palate-type malformations. Postnatally, PDGF R $\alpha$  is implicated in gliomas and fibrotic disorders of lung, heart and skin (scleroderma) (5- 7).

**References:**

1. Andrae, J. *et al.* (2008) *Genes Dev.* **22**:1276.
2. Heldin, C-H. and B. Westermark (1999) *Physiol. Rev.* **79**:1283.
3. Do, M.S. *et al.* (1992) *Oncogene* **7**:1567.
4. Klinghoffer, R.A. *et al.* (2002) *Dev. Cell* **2**:103.
5. Martinho, O. (2009) *Br. J. Cancer* **101**:973.
6. Olson, L.E. and P. Soriano (2009) *Dev. Cell* **16**:303.
7. Baroni, S.S. *et al.* (2006) *N. Engl. J. Med.* **354**:2667.